Tscan Therapeutics, INC Schedule 13G passive stakes

Lynx1 Capital Management LP and Weston Nichols have reported beneficial ownership of 13.1% of TScan Therapeutics, Inc. common stock as of June 30, 2026.

Several Biotechnology Value Funds and associated entities have updated their beneficial ownership filings for TScan Therapeutics, Inc., reporting their holdings as of June 30, 2026.

Biotechnology Value Fund and affiliates report a 9.99% beneficial ownership stake in TScan Therapeutics, Inc. following recent warrant exercises.

Lynx1 Capital Management LP and Weston Nichols have disclosed a 15.0% beneficial ownership stake in TScan Therapeutics, Inc.'s Voting Common Stock.

Adage Capital Management, L.P. and its principals reported a 2.52% beneficial ownership stake in TScan Therapeutics, Inc., primarily through warrants.

BlackRock, Inc. has filed an amended Schedule 13G, revealing a 1.8% beneficial ownership stake in TScan Therapeutics, Inc. as of June 30, 2025.

A group of investment entities associated with Biotechnology Value Fund (BVF), led by Mark N. Lampert, has disclosed a combined 9.99% beneficial ownership stake in TScan Therapeutics, Inc., primarily through common stock and pre-funded warrants.

EcoR1 Capital, LLC, Oleg Nodelman, and EcoR1 Capital Fund Qualified, L.P. have filed an amended Schedule 13G, disclosing their beneficial ownership of 1.3% of TScan Therapeutics, Inc.'s Voting Common Stock as of March 31, 2025.

BlackRock, Inc. has filed an amended Schedule 13G, reporting a 5.4% passive beneficial ownership stake in TScan Therapeutics, Inc. as of March 31, 2025.

K2 HealthVentures Equity Trust LLC, along with its managing members, has reported a beneficial ownership of 6.9% in TScan Therapeutics, Inc., totaling 3,602,700 shares as of December 31, 2024, primarily due to the conversion of $15 million in term loans into equity.

Lynx1 Capital Management LP and Weston Nichols have disclosed a beneficial ownership of 10.9% in TScan Therapeutics, Inc., totaling 5,357,347 shares of Voting Common Stock as of December 31, 2024.

Adage Capital Management, L.P. and its principals have reported an updated 7.13% beneficial ownership stake in TScan Therapeutics, Inc. as of December 31, 2024, through an amended Schedule 13G filing.